Dhuwit awis perusahaan Accuray Inc. (ARAY)

ARAY (Accuray Inc) - tandha merek perusahaan

High patent barriers and the complexity of physician training create a durable moat for Accuray Incorporated (ARAY). Free cash flow levels demonstrate the liquidity of the business, with the latest parameter standing at 0.04. Stability is underpinned by global reach and service contracts, while the primary capital is generated by sales of CyberKnife robotic systems to leading oncology centers.

Accuray Inc - Sisa dhuwit perusahaan ARAY (periode 04.07.2022 - 21.11.2026)

Accuray (ARAY) - rincian metrik lan laporan keuangan

Analisis fundamental perusahaan:ARAY Accuray Inc
Produk mawa merek accuray.com

Accuray Incorporated (ARAY) focuses on the expansion of CyberKnife systems and the integration of AI into radiation therapy. By analyzing changes in cash asset volume, an investor assesses the liquid reserve available for scaling the business without incurring external debt. This metric reflects the balance between operational resilience and capital efficiency. A stable cash level confirms the company's ability to fund technological modernization and expansion into emerging markets.

Pesaing Accuray Incorporated (ARAY)

Volume dana dhuwit perusahaan ONC|HALO - Cadangan dhuwit perusahaan|Revolution Medicines - Dhuwit awis perusahaan|Volume dana dhuwit perusahaan Ascentage Pharma AAPG|CGON - Dana dhuwit perusahaan|Total volume dana dhuwit perusahaan URGN|BCAX: Volume dana dhuwit perusahaan|PSNL - Aset likuid perusahaan|ERAS (Erasca Inc) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Delcath Systems Inc DCTH|Dana dhuwit perusahaan YmAbs (YMAB)|Aset likuid perusahaan Aura Bio|Volume dana dhuwit perusahaan CADL (Candel Therapeutics Inc.)|Aset likuid perusahaan SELLAS Life Sciences Group Inc. (SLS)|actuatetherapeutics.com - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Citius Oncology|HURA: Volume dana dhuwit perusahaan|Total volume dana dhuwit perusahaan TARA (Protara)|FATE (fatetherapeutics.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Aadi Bioscience WHWK|Volume dana dhuwit perusahaan TCRX|CSBR - Cadangan dhuwit perusahaan|XBiotech - Dhuwit awis perusahaan|CEL-SCI Corporation (CVM) - Cadangan dhuwit perusahaan|OSTX - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Radiopharm Theranostics Ltd|ARTV (artivabio.com) - Dhuwit awis perusahaan|ANL (Adlai Nortye Ltd) - Dana dhuwit perusahaan|Dhuwit awis perusahaan VERU|Tempest Therapeutics (TPST) - Aset likuid perusahaan|Volume dana dhuwit perusahaan XLO|Dhuwit awis perusahaan Renovaro RENB|Volume dana dhuwit perusahaan MURA (Mural Oncology PLC)|KAPA - Dhuwit awis perusahaan|OnKure Therapeutics - Volume dana dhuwit perusahaan|w2.cytomed.sg - Gunggung dana dhuwit perusahaan|Curis Corp (CRIS) - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Apollomics Corp (APLM)|Dana dhuwit perusahaan Tharimmune|Volume dana dhuwit perusahaan advanbiomed.com|Dana dhuwit perusahaan Genprex, Inc (GNPX)|Aset likuid perusahaan Calidi Biotherapeutics, Inc.|Volume dana dhuwit perusahaan SBFM (Sunshine Biopharma Inc.)|XBIO - Dhuwit awis perusahaan|SLRX: Dhuwit awis perusahaan|Sisa dhuwit perusahaan PPBT (Purple Biotech Ltd.)|AONC: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan BeOne Medicines (BGNE)|Dana dhuwit perusahaan Checkpoint Therapeutics, Inc.|Dhuwit awis perusahaan Elevation Oncology (ELEV)|Dana dhuwit perusahaan iCAD Corp (ICAD)|Dhuwit awis perusahaan Ikena IKNA|Volume dana dhuwit perusahaan NTBL (notablelabs.com)|VIRX - Dhuwit awis perusahaan|MOR: Dhuwit awis perusahaan|NAYA - Volume dana dhuwit perusahaan|Ascentage Pharma (AAPGV) - Dana dhuwit perusahaan